Edwards Lifesciences announces presentation of one-year SAPIEN 3 data
Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...
Edwards Lifesciences announces positive results in one year TAVI trial
Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...
Hold Rating Maintained on Edwards Lifesciences Despite Positive SAPIEN 3 Ultra RESILIA Valve Data
Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...
MassDevice9h
Edwards reports ‘excellent’ outcomes for Sapien 3 Ultra Resilia TAVR system
Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...
Le Lézard15h
Edwards' SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 ...
Yahoo Finance3d
Edwards Lifesciences Corporation (EW)
presented during the lat JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in ...
GSA Capital Partners LLP Invests $481,000 in Edwards Lifesciences Co. (NYSE:EW)
GSA Capital Partners LLP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) in the third ...
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages
Edwards Lifesciences Co. (NYSE:EW – Get Free Report) has been given a consensus recommendation of “Hold” by the twenty-six ratings firms that are covering the firm, MarketBeat reports. Sixteen ...